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The association between naturally 
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antibodies to the PfRH5 invasion 
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Plasmodium falciparum malaria
Rupert Weaver1,2, Linda Reiling1, Gaoqian Feng1, Damien R. Drew1, Ivo Mueller3,4,5, 
Peter M. Siba6, Takafumi Tsuboi7, Jack S. Richards1,2,8, Freya J. I. Fowkes1,9,10 & 
James G. Beeson1,2,8
Understanding the targets and mechanisms of human immunity to malaria is important for advancing 
the development of highly efficacious vaccines and serological tools for malaria surveillance. The 
PfRH5 and PfRipr proteins form a complex on the surface of P. falciparum merozoites that is essential 
for invasion of erythrocytes and are vaccine candidates. We determined IgG subclass responses to 
these proteins among malaria-exposed individuals in Papua New Guinea and their association with 
protection from malaria in a longitudinal cohort of children. Cytophilic subclasses, IgG1 and IgG3, were 
predominant with limited IgG2 and IgG4, and IgG subclass-specific responses were higher in older 
children and those with active infection. High IgG3 to PfRH5 and PfRipr were significantly and strongly 
associated with reduced risk of malaria after adjusting for potential confounding factors, whereas 
associations for IgG1 responses were generally weaker and not statistically significant. Results further 
indicated that malaria exposure leads to the co-acquisition of IgG1 and IgG3 to PfRH5 and PfRipr, as 
well as to other PfRH invasion ligands, PfRH2 and PfRH4. These findings suggest that IgG3 responses 
to PfRH5 and PfRipr may play a significant role in mediating naturally-acquired immunity and support 
their potential as vaccine candidates and their use as antibody biomarkers of immunity.
Plasmodium falciparum malaria is a leading cause of morbidity and mortality globally, particularly in young children1. 
The development of an effective vaccine would provide a powerful tool for malaria control and elimination2,3. 
A detailed knowledge of human immunity to malaria, especially identifying key targets and effector mechanisms 
that mediate protection, is needed to advance vaccine development. In malaria endemic areas individuals acquire 
immunity to symptomatic infection after repeated exposure, supporting the rationale for the development of a 
P. falciparum vaccine that is capable of generating protective immunity against malaria3–8. Acquired immunity 
largely targets blood-stage antigens and is proposed to function by limiting parasite replication, thereby prevent-
ing the development of high-density parasitemia and symptomatic malaria3,9. Antibodies to P. falciparum blood 
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stage antigens have been shown to be an important part of this protective immune response3,4,8,10–15. However, the 
principal targets and precise mechanisms of protective immune responses remain poorly understood.
A promising emerging vaccine candidate is P. falciparum reticulocyte binding-like homologue protein 
(PfRH5)16,17 which has recently been reported to elicit protective antibody responses in a non-human primate 
vaccine trial18. The PfRH family of invasion ligands is expressed by P. falciparum merozoites and includes PfRH1, 
PfRH2a, PfRH2b, PfRH4 and PfRH5. While all five members of this family play important roles in merozoite 
invasion, only PfRH5 appears essential to blood stage replication of P. falciparum in vitro13,19–21. The PfRH5 pro-
tein is located in the rhoptries, but is secreted onto the surface of merozoites prior to RBC invasion13. After its 
release, PfRH5 forms a complex on the merozoite surface with PfRipr (P. falciparum PfRH5 interacting protein)22 
and CyRPA (Cysteine-rich protective antigen)23,24. The exact mechanism by which this complex is tethered to the 
merozoite surface remains the subject of some debate. It has been proposed that CyRPA is GPI-anchored to the 
merozoite surface24, whereas others have suggested that it is secreted23 leaving open the possibility that the PfRH5 
complex attaches to the merozoite surface through an additional or alternate component. PfRH5 binds to basigin 
on the surface of red blood cells (RBC)25. Antibodies to all three components of the complex can inhibit parasite 
invasion13,22,24.
Individuals naturally exposed to P. falciparum in malaria endemic regions of Africa and Papua New Guinea 
have been shown to develop anti-PfRH5 antibodies5,26,27, and antibodies to PfRH5 were associated with protec-
tion from symptomatic malaria in malaria-endemic regions of Papua New Guinea5, and Mali27. Antibodies to 
PfRipr have also been associated with protection from malaria in children5. Affinity-purified antibodies to PfRH5 
from naturally-exposed individuals were shown to inhibit P. falciparum growth in vitro26,27. These findings sug-
gest that PfRH5 complex is an important target of immunity. However the nature of the IgG subclass response to 
PfRh5 and PfRipr and how this relates to acquired protective immunity has not been established. The aims of the 
present study were to define the nature of IgG subclass responses to PfRH5 and PfRipr, and determine the associ-
ations between subclass-specific responses and the prospective risk of malaria. We tested the hypothesis that the 
response to PfRH5 and Pfripr is restricted to certain IgG subclasses, and that specific IgG subclass responses may 
be more strongly associated with protection. Furthermore, we aimed to assess the potential influence of host age 
and P. falciparum infection on acquisition of these antibodies and their relationship to the acquisition of antibod-
ies to other PfRH invasion ligands.
Methods
Study population. The study population and details of the cohort study, conducted between June and 
December 2004, have been described previously28. Briefly, plasma samples were obtained from a treatment to 
re-infection study of 206 school children from Mugil and Megiar, Madang Province, Papua New Guinea. The 
children were aged between 5–14 years with a median age of 9.3 years. Blood samples were taken at enrolment 
(baseline). Following enrolment, children were treated with artesunate to clear infection and then actively mon-
itored fortnightly for 6 months for re-infection and symptomatic malaria episodes. Re-infection and treatment 
failure were distinguished by MSP2 genotyping. Plasma samples taken at enrolment were used for analysis by 
ELISA. Negative controls were taken from malaria-naïve Australian residents and positive controls were from 
malaria-exposed adults from PNG and were used to standardise assays and account for variation between plates.
Ethics approval was obtained from the Medical Research Advisory Committee, PNG, the Walter and Eliza 
Hall Institute of Medical Research Ethics Committee, and The Alfred Human Research Ethics Committee and 
the study was conducted in accordance with the protocol and relevant guidelines. Written informed consent was 
obtained from all study participants or their guardians (for children).
Recombinant proteins. Recombinant PfRH5 and PfRipr were expressed in a wheat germ cell-free expres-
sion system (WGCF)29. PfRH5 comprised the full ectodomain (amino acid residues 25–526). PfRipr com-
prised amino acids 238–3685. Both proteins were assessed for quality and purity by SDS-PAGE and Western 
blot (reduced and non-reduced), as described5. Previous studies have demonstrated that antibodies measured 
by ELISA to recombinant PfRH5 and PfRipr are specific to malaria-exposed individuals, and the recombinant 
PfRH5 was shown to be functionally active, binding to the RBC surface, and able to generate inhibitory antibodies 
when used in immunizations30.
Antibodies by ELISA. ELISA (Enzyme Linked Immunosorbent Assays) were performed in 96-well plates 
(NUNC, Denmark) using established methods described elsewhere6. All proteins, sera and reagents were used at 
50 μ l/well. Proteins were coated onto plates in PBS solution at a concentration of 2 μ g/ml and incubated overnight 
at 4 °C. Plates were blocked with 200 μ l of 10% skim milk in PBS/0.05% Tween for 2 hours. Plasma samples were 
tested at 1:250 in 5% milk in PBS/0.05% Tween solution for 2 hours at room temperature. Mouse anti-human 
IgG1 and 3 (Invitrogen life technologies, USA) were used at 1:500 to detect IgG subclass antibodies and incu-
bated for 1 hour at room temperature. Tertiary antibody (goat anti-mouse HRP conjugated, Merck Millipore, 
USA) was added at 1:250 dilution for 1 hour at room temperature. ABTS liquid substrate system (Sigma-Aldrich, 
USA) was added to measure enzymatic activity. All wash steps were done with PBS/0.05% Tween. OD was meas-
ured at 405 nm. Plate-to-plate variation was standardized using positive controls on each plate and plasma from 
non-immune blood donors were used as negative controls. Seropositivity was defined as an OD above the highest 
value obtained from the selection of negative controls. All samples were tested in duplicate. Reagents and sera 
were tested in serial dilution to determine the optimum dilution for testing the cohort. Previous studies have 
shown the use of mid-point dilutions provide results that strongly correlate with end-point titrations; therefore 
one midpoint dilution was chosen10,31. Data for total IgG to PfRH5 and PfRipr were previously determined5. Pilot 
experiments were performed to ensure the specificity of subclass detection antibodies, which were validated 
against purified IgG subclass antibodies (Invitrogen). Optimization was carried out for all reagents, sera and 
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incubation time to determine the optimal parameters to ensure a good separation between high, medium and 
low responders. Optimisation experiments included (i) testing secondary and tertiary antibodies across a range 
of dilutions in ELISA with each antigen, (ii) testing a selection of subject’s samples across a range of dilutions in 
ELISAs with antigen and IgG subclass, and (iii) testing recombinant antigens at a range of coating concentrations.
Statistical analysis. Kruskal-Wallis and chi-squared tests were used to determine the association of contin-
uous and categorical variables, respectively, with categorical variables. Correlations between antibody responses 
were assessed using Spearman’s rho (ρ ). To assess the association between subclass responses and protection 
from symptomatic malaria, children were classified into three equal groups of high, medium and low responders, 
according to the OD of antibody responses; children who were negative for antibodies were included in the low 
responder group6. A symptomatic episode of P. falciparum malaria was defined as a fever (> 37 °C) and a para-
sitemia > 5000/μ l28. Kaplan-Meier survival analyses were performed for time-to-first episode of symptomatic 
P. falciparum malaria, with subjects stratified as high, medium or low responders, and a log rank test was per-
formed to compare response tertiles. Cox proportional hazard models were used to determine the association 
between antibody response categories and risk of symptomatic P. falciparum malaria adjusting for potential con-
founders6. A range of demographic, clinical and biological variables were assessed as potential confounders of 
associations between antibodies and malaria outcomes. Only host age and location of residence were identified 
as being significantly associated with antibodies and malaria outcomes6,28. Therefore, these two variables were 
included in the adjusted analyses. Other variables (consider a priori), such as parasitemia at enrolment, and 
red blood cell genetic polymorphisms, were not significantly associated with the outcome of malaria. Age was 
used as binary variable (≤ 9 years, > 9 years), as previous studies indicated that this stratification was the most 
informative approach for assessing the effect of age6,28. Of note, parasitemia status at enrolment and red blood cell 
polymorphisms were not associated with malaria outcomes28. IgG1 response groups showed non-proportional 
hazards; therefore an interaction term between antibody level and time was included in the model (using three 
time categories t = 0–100, t = 100–150 and t > 150 days since study commencement)7.
Results
Subclass response to PfRH5 and PfRipr. To determine the predominant IgG subclass response to PfRH5 
and PfRipr, a selection of malaria exposed PNG adults (n = 24) who were resident in Madang Province were 
tested. IgG1 and IgG3 were the predominant subclass response to both antigens (seroprevalence for PfRH5 IgG1: 
91.0%, IgG3: 86%; PfRipr IgG1: 63%, IgG3: 59%; OD levels shown in Fig. 1). The predominance of IgG1 and IgG3 
to these antigens is similar to IgG subclass responses to other merozoite antigens, including other PfRH family 
members PfRH2 and PfRH47,12. Very few individuals were classified as seropositive for IgG4 to PfRH5 (4.5%) or 
PfRipr (4.5%). There was also a low seroprevalence for IgG2 to PfRipr (13%), but a higher proportion were clas-
sified as seropositive for IgG2 to PfRH5 (34.8%). However, it should be noted that levels of IgG2 reactivity were 
generally very low (Fig. 1), even though some samples were classified as seropositive. Given the limited reactivity 
of IgG2 and IgG4 observed, only IgG1 and IgG3 responses to PfRH5 and PfRipr were determined for the main 
study.
In the children’s cohort, IgG1 and IgG3 to PfRH5 and PfRipr had higher median ODs compared to 
malaria-naïve negative controls indicating the specificity of P. falciparum antibody responses (p < 0.001). IgG3 
was the predominant subclass response against both antigens with a higher seroprevalence compared to IgG1 
(p < 0.001) (PfRH5 seroprevalence: IgG1 32%, IgG3 57.3%; PfRipr seroprevalence: IgG1 47%, IgG3 62.1%).
Association of IgG subclass responses to PfRH5 and PfRipr with age and concurrent parasitaemia. 
To investigate the relationships between age and IgG subclasses responses (IgG1 and IgG3) to PfRH5 and PfRipr, 
seroprevalence was compared between younger and older children (Fig. 2). The seroprevalence of total IgG to 
PfRH5 and PfRipr was significantly higher in older children compared to younger children (PfRH5, > 9 yrs: 
65.2%, <9 yrs: 38.5%, p < 0.001; PfRipr > 9 yrs: 50.0%, <9 yrs: 38.5%, p = 0.07). Higher seroprevalence of IgG1 
and IgG3 subclass responses were also found in older compared to younger children for both PfRH5 and PfRipr 
(PfRH5 IgG1: > 9 yrs: 41.7%, <9 yrs: 20.9%, p = 0.002; IgG3: > 9 yrs: 67.8%, <9 yrs: 44.0%, p < 0.001; PfRipr, IgG1, 
> 9 yrs: 48.7%, <9 yrs: 36.3%, p = 0.07; IgG3 > 9 yrs: 69.6%, <9 yrs: 52.8%, p = 0.01) (Fig. 2).
Previous studies have shown individuals with active P. falciparum infection generally have higher levels 
of antibodies to merozoite antigens4,6,32. In our cohort, IgG3 and IgG1 responses to PfRH5 were significantly 
higher in PCR positive compared to PCR negative individuals. The prevalences of IgG3 responses were 43.3 and 
64% for PCR(− ) and PCR(+ ), respectively, (p = < 0.001); prevelances of IgG1 responses were 25.4% and 36.0% 
(p = 0.002). PfRipr-specific IgG3 seroprevalence was higher in PCR positive compared to PCR negative individ-
uals (PCR(− ): 53.7%, PCR(+ ): 66.2%, p = 0.01), but the difference was less marked for IgG1 responses (PCR(− ): 
53.7%, PCR(+ ): 66.2%, p = 0.07) (Fig. 3).
Relationships between antibody responses. Responses to PfRH5 were significantly positively corre-
lated with each other (Table 1). Total IgG to PfRH5 was more strongly correlated with the predominant response 
of IgG3 than with IgG1 (IgG3: ρ = 0.76, IgG1: ρ = 0.58, p < 0.001). The two subclass responses to PfRH5 were also 
moderately correlated with one another (ρ = 0.49, p < 0.001). Total IgG to PfRipr was more strongly correlated 
with the major response of IgG3 compared to IgG1 (IgG3: ρ = 0.79 p < 0.001, IgG1: ρ = 0.69 p < 0.001). The two 
subclasses responses were also moderately correlated with one another (ρ = 0.53, p < 0.001). There was a very 
strong correlation between total IgG responses to both antigens (ρ = 0.82, p < 0.001). The predominant IgG3 
responses to each antigen were also strongly correlated (ρ = 0.68, p < 0.001).
To investigate the co-acquisition of antibodies to different antigens, the total IgG and subclass responses to 
PfRH5 and PfRipr were compared to previously published data on IgG responses to other PfRH family proteins; 
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PfRH2 (construct PfRH2-20307) and PfRH4 (construct PfRH4.912). Total and subclass IgG levels to all PfRH 
proteins were significantly correlated with each other (ρ range: 0.15–0.82, p < 0.05) (Table 1). The predominant 
IgG3 responses to PfRH5 were significantly moderately correlated to PfRH4 IgG1 and IgG3 (ρ = 0.32 and 0.46, 
respectively, p < 0.001) and PfRH2 IgG1 and IgG3 (ρ = 0.40 and 0.53, respectively, p < 0.001). The major subclass 
response to PfRipr, IgG3, was more strongly correlated with IgG3 responses to PfRH2 (ρ = 0.51, p < 0.001) and 
PfRH4 (ρ = 0.45, p < 0.001). These findings suggest there is co-acquisition of antibodies to PfRH5, PfRipr and 
other PfRH ligands following exposure to P. falciparum infection.
Associations between IgG and subclass responses and clinical malaria. To investigate the asso-
ciation between antibody responses and protection from symptomatic P. falciparum malaria, the children were 
divided into three equal tertiles representing high, medium and low antibody levels for each subclass response 
and survival analyses were performed. In Kaplan-Meier survival analyses (unadjusted), there were significant 
differences between the three IgG subclass groups, with high responders having a longer time to first symptomatic 
P. falciparum episode than medium and low responders for both PfRH5 and PfRipr (PfRH5 IgG1: p = 0.004, IgG3: 
p < 0.001; PfRipr IgG1, IgG3 both p < 0.001) (Fig. 4).
After adjusting for the confounding effects of age and location of residence, individuals with high levels of 
total IgG to PfRH5 had a 65% lower risk of symptomatic P. falciparum malaria compared to individuals with low 
IgG levels, as reported previously5 (aHR 0.35, 95% CI: 0.12–0.96, p = 0.04) (Table 2). Similarly, individuals who 
were high responders for IgG3 to PfRH5 had a 65% decreased risk of symptomatic falciparum malaria compared 
to those who were classified as low responders, after adjustment for confounders; there was also a reduced risk of 
malaria for high IgG1 responders, but this did not reach statistical significance (IgG3: aHR 0.35, CI: 0.17–0.71, 
p = 0.03; and IgG1 aHR 0.46, CI: 0.16–1.29, p = 0.14) (Table 2). Total IgG against PfRipr was significantly associ-
ated with a 76% reduced risk of symptomatic P. falciparum malaria after adjusting for potential confounders, as 
previously reported5 (aHR: 0.24, 95% CI: 0.08–0.73, p = 0.01). As found for PfRH5 responses, high levels of IgG3 
to PfRipr were strongly and significantly associated with protection from symptomatic P. falciparum malaria after 
adjusting for confounders (HvL responders aHR 0.36, 95% CI: 0.018-0.72, p = 0.004). Associations were weaker 
for IgG1 to PfRipr, and did not reach statistical significance after adjusting for confounders (aHR: 0.48 95% CI 
0.19–1.26, p = 0.14).
Figure 1. Reactivity of IgG subclasses to PfRH5 and PfRipr in PNG adults. Optical density (OD) values 
obtained for a selection of sera from malaria exposed PNG adults (n = 24) for (A) PfRH5 and (B) PfRipr specific 
IgG subclass reactivity. Bars represent median value. Error bars represent interquartile range.
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Discussion
In this study we found that cytophilic antibodies IgG1 and IgG3 were the predominant subclass responses to 
PfRH5 and PfRipr, which are present as an invasion complex on the merozoite surface. Interestingly, IgG3 
responses were most strongly associated with protection from malaria in a longitudinal cohort study of children, 
whereas protective associations for IgG1-specific responses were weaker and did not reach statistical significance 
after adjusting for confounding variables. These findings provide further support for PfRH5 and PfRipr as malaria 
vaccine candidates and suggest that the IgG3 response is more important in mediating protection.
Our initial studies in a selection of adults indicated that IgG1 and IgG3 were the predominant responses 
to PfRH5 and PfRipr, with little IgG2 and IgG4 reactivity. In the larger children’s cohort, both IgG1 and IgG3 
were prevalent, but IgG3 responses were significantly more common for both antigens. A prior study in Senegal 
found that IgG1 responses were more prevalent than IgG3 among adults (69% vs. 31% respectively), although the 
sample size in that study was small (n = 19)27. Previous studies suggest that the nature of the subclass response 
appears to be influenced by intrinsic properties of the antigen, the level of exposure to P. falciparum among indi-
viduals, and host factors4,6,10. We found that IgG subclass responses were somewhat higher among older children, 
consistent with acquisition of antibodies with increasing exposure to malaria4,7,6. Age is a measure of the broad 
level of exposure in coastal areas of PNG, which has year-round malaria transmission28. However, age may also 
be associated with changes in the physiological or immunological development; Baird et. al33. suggested that 
intrinsic changes in the immune response can contribute to protection. Therefore, our analyses were adjusted for 
age to account for the potential confounding influence of age6. IgG1 and IgG3 levels to both antigens tended to 
be higher in children with PCR-detectable P. falciparum infection compared to uninfected children. The overall 
trend of increased IgG subclass responses in those with concurrent parasitemia is consistent with other studies 
and reflect potential boosting of antibody responses with infection6,34,35.
A strength of this study is the longitudinal study design that enabled prospective examination of the associa-
tion between antibodies and subsequent malaria episodes. We found that higher levels of IgG1 and IgG3 against 
PfRH5 and PfRipr at enrolment were associated with protection from subsequent symptomatic P. falciparum 
malaria during follow-up. There was evidence of a dose-response effect, as the risk of symptomatic P. falciparum 
malaria was significantly reduced in those with high compared to medium and low antibody levels. Protective 
associations were substantially stronger for IgG3 responses to PfRH5 and PfRipr than IgG1 responses, and only 
the associations between IgG3 and protection remained significant after adjustment for potential confounders. 
Interestingly, previous studies of IgG subclass responses to other members of the PfRH invasion ligand family 
found that IgG3 responses were strongly associated with protection from malaria7,12. Furthermore, IgG3 was also 
Figure 2. Seroprevalence of total IgG and subclass response to PfRH5 and PfRipr by age. IgG seroprevalence 
to PfRH5 and PfRipr recombinant proteins measured by ELISA. Results are shown as percentage seropositive.. 
Error bars indicate standard error of proportion (SE). Results are shown by Age (<9 or > 9 years of age). Top 
row: PfRH5. Bottom row: PfRipr. Results are shown for (A)/(D) Total IgG, (B)/(E). IgG1 and (C)/(F) IgG3 left 
to right. P values indicate chi square test.
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found to have the strongest protective association for the EBA invasion ligands, which act co-operatively with 
PfRH ligands, even when IgG1 was the predominant subclass produced4. High IgG3 responders to PfRH5 and 
PfRipr had a stronger association with protection compared to individuals with medium levels of IgG3 raising the 
possibility that there may be a threshold level of antibodies required to mediate effective protection. Protective 
associations for IgG3 responses to PfRH5 and PfRipr were strong in this cohort (HR values 0.26 and 0.29, respec-
tively). The strength of these protective associations was stronger than we have previously reported in this cohort 
for IgG3 responses to some other antigens, such as MSP1 and MSP2, and similar to protective associations for 
IgG3 responses to EBA175, EBA140, and PfRH24,6,7. In this study we evaluated antibodies only at enrolment. In 
future studies it would be valuable to evaluate PfRH5 and PfRipr antibody dynamics over time and evaluate the 
Figure 3. Seroprevalence of total IgG and subclass response to PfRH5 and PfRipr by concurrent 
parasitemia measured by PCR. Results are shown as percentage seropositive, as determined by ELISA. Error 
bars indicate standard error of proportion (SE). Results are shown by parasitemic status at enrolment (PCR(− ) 
or PCR(+ )). Top row: PfRH5 Bottom row: PfRipr. Results are shown for (A)/(D) Total IgG, (B)/(E) IgG1 and 
(C)/(F) IgG3 left to right. P values indicate chi square test.
PfRh5 PfRipr PfRh2 PfRh4
IgG IgG1 IgG3 IgG IgG1 IgG3 IgG IgG1 IgG3 IgG IgG1 IgG3
PfRh5 IgG … … … … … … … … … … … … 
IgG1 0.58** … … … … … … … … … … … 
IgG3 0.76** 0.49** … … … … … … … … … … 
PfRipr IgG 0.82** 0.56** 0.76** … … … … … … … … … 
IgG1 0.41** 0.46** 0.41** 0.69** … … … … … … … … 
IgG3 0.64** 0.52** 0.68** 0.79** 0.53** … … … … … … … 
PfRh2 IgG 0.36** 0.19* 0.41** 0.34** 0.27** 0.31** … … … … … … 
IgG1 0.35** 0.19** 0.40** 0.34** 0.29** 0.32** 0.88** … … … … … 
IgG3 0.51** 0.23** 0.53** 0.45** 0.27** 0.51** 0.43** 0.46** … … … … 
PfRh4 IgG 0.32** 0.15* 0.35** 0.3** 0.24** 0.28** 0.64** 0.69** 0.41** … … … 
IgG1 0.32** 0.15* 0.32** 0.28** 0.22* 0.28** 0.64** 0.70** 0.42** 0.93** … … 
IgG3 0.44** 0.15* 0.46** 0.39** 0.35** 0.45** 0.35** 0.44** 0.55** 0.39** 0.39** … 
Table 1.  Spearman’s ρ between IgG, IgG1 and IgG3 to PfRH family proteins: PfRH5; PfRipr; PfRH2; 
PfRH4. Spearman ρ are shown for total IgG and subclasses IgG1 and 3 to PfRH5; PfRipr; PfRH4; PfRH2 in 206 
Papua New Guinean children. * p < 0.05, ** p < 0.001. PfRH2 construct was PfRH2.2030. PfRH4 construct was 
PfRH4.9.
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relationship between antibody levels prior to reinfection and subsequent risk of developing high density para-
sitemia. In our study we used recombinant proteins expressed using a wheat germ cell free expression system, 
and the antigens have been previously validated5. Others have found that IgG measured to recombinant PfRH5 
expressed in E.coli and PfRipr expressed in baculovirus-infected Hi-5 cells among this same PNG cohort of chil-
dren were associated with protection36, suggesting that the associations between PfRH5 or PfRipr responses and 
protection from malaria are robust.
Defining the nature of IgG subclass responses to PfRH5 and PfRipr, and their associations with protective 
immunity, is important because different subclasses have different immune effector functions37,38. As such, under-
standing the subclass response provides further insight into the possible biological function of antibodies and 
their potential role in protection. IgG1 and IgG3 are cytophilic and engage Fc-receptors to promote opsonic 
phagocytosis or killing by neutrophils; recent studies have reported that antibodies mediating opsonic phagocy-
tosis of merozoites, or neutrophil-mediated killing, are associated with protection from malaria in children15,39. 
How IgG1 and IgG3 may differ in their opsonic phagocytosis functions for merozoites is not known, but differ-
ences between IgG1 and IgG3 have been reported in other systems37,40. IgG1 and IgG3 can also activate comple-
ment, and recent studies have suggested that human antibodies to merozoites interact with complement to inhibit 
invasion41. IgG3 is believed to be a more potent activator of complement38. Given the location of PfRH5 and 
PfRipr on the merozoite surface, their important role in invasion, and the finding that IgG3 is strongly associated 
with protection from malaria, future studies are needed to further evaluate the functional activity of antibodies 
to PfRH5 and PfRipr.
Total IgG, IgG1 and IgG3 to all PfRH family proteins were correlated, with the highest correlations observed 
with the predominant IgG subclass responses. IgG1 and IgG3 responses to PfRH5, or PfRipr, were found to be 
significantly correlated with each other. Furthermore, IgG1 and IgG3 to other PfRH family proteins, PfRH2 and 
PfRH4, were also correlated with PfRH5 and PfRipr responses. The predominant IgG subclass responses for each 
antigen were most strongly correlated. These findings indicate the co-acquisition of antibodies to multiple PfRH 
invasion ligands following exposure to P. falciparum infection, supporting a view that immunity to malaria is 
mediated by a repertoire of antibodies to multiple invasion ligands.
Figure 4. Risk of symptomatic P. falciparum episode during follow-up relative to IgG1 and IgG3 to PfRH5. 
Kaplan-Meier curves show the proportion of children that remained free of malaria episodes over time for IgG 
subclass responses against PfRH5 and PfRipr (A) IgG1 to PfRH5; (B) IgG3 to PfRH5; (C) IgG1 to PfRipr; (D) 
IgG3 to PfRH5. Antibody responses were divided into 3 equal response groups: high (green line), medium (red 
line), and low (blue line) antibody reactivity. Unadjusted data are shown. Wilcoxon log rank tests were carried 
out: (A) p = 0.004; (B) p < 0.001; (C) p < 0.001; (D) p < 0.001 Symptomatic P. falciparum infection was defined 
as fever (> 37 °C) plus a parasite load of 5000 parasites/μ l.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:33094 | DOI: 10.1038/srep33094
Conclusion
This is the first study to examine the association of naturally-acquired IgG subclass responses to PfRH5 and 
PfRipr with protection from symptomatic P. falciparum malaria, finding that IgG3-specific responses are 
most strongly associated with immunity. This knowledge provides important insights into potential mech-
anisms mediating protection, and identifies possible antibody biomarkers of protective immunity that may 
have important applications for sero-surveillance in P. falciparum malaria endemic areas42. Further studies are 
needed to evaluate whether IgG3 responses to PfRH5 or PfRipr may be better biomarkers of protective immu-
nity than total IgG responses to these antigens. The results from this study add to evidence supporting PfRH5 
and PfRipr as potential candidates for inclusion in a multicomponent vaccine. Understanding the functional 
immunological significance between IgG1 and IgG3 responses to these antigens may be important for deter-
mining whether vaccines based on these antigens need to generate a particular IgG subclass response in order 
to maximize vaccine efficacy.
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